Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13333203 | 0.91 | CYP2C19 (0.46) | CYP2C19L3MBTL1SMN1; SMN2POLBGAA | |
| SCHEMBL22912360 | 0.91 | CYP2C19 (0.46) | CYP2C19L3MBTL1SMN1; SMN2POLBGAA | |
| SCHEMBL26613582 | 0.90 | CYP2C19 (0.41) | CYP2C19L3MBTL1SMN1; SMN2POLBGAA | |
| Cpi 613 SCHEMBL26613507 | 0.87 | CYP2C19 (0.54) | CYP2C19SMN1; SMN2POLBLMNAMAPT | |
| SCHEMBL22912362 | 0.82 | CYP2C19 (0.44) | CYP2C19L3MBTL1SMN1; SMN2POLBGAA | |
| SCHEMBL26613554 | 0.80 | CYP2C19 (0.50) | CYP2C19L3MBTL1SMN1; SMN2POLBGAA | |
| SCHEMBL17381367 | 0.79 | CYP2C19 (0.49) | CYP2C19SMN1; SMN2POLBHTTLMNA | |
| Cpi 613 SCHEMBL1062218 | 0.79 | CYP2C19 (0.59) | CYP2C19SMN1; SMN2LMNAMAPTALDH1A1 | |
| Cpi 613 SCHEMBL13333201 | 0.79 | CYP2C19 (0.59) | CYP2C19SMN1; SMN2LMNAMAPTALDH1A1 | |
| Cpi 613 SCHEMBL26613605 | 0.78 | CYP2C19 (0.55) | CYP2C19SMN1; SMN2POLBGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348373-A1 | DEUTERATED DERIVATIVES OF 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID | RAFAEL PHARMACEUTICALS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348373-A1 | DEUTERATED DERIVATIVES OF 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID | SCD5, DHCR7, BCL6 | CYP2C19 1131/4885L3MBTL1 2896/4885SMN1; SMN2 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.